Valuation: ProKidney Corp.

Capitalization 253M 216M 198M 187M 347M 24.19B 350M 2.35B 917M 11.47B 948M 928M 39.87B P/E ratio 2026 *
-2.3x
P/E ratio 2027 * -2.19x
Enterprise value 120M 102M 93.68M 88.68M 164M 11.46B 166M 1.12B 435M 5.44B 449M 440M 18.89B EV / Sales 2026 *
329x
EV / Sales 2027 * 18.9x
Free-Float
14.65%
Yield 2026 *
-
Yield 2027 * -
1 day-4.84%
1 week-7.81%
Current month-6.84%
1 month-9.23%
3 months-10.61%
6 months-33.96%
Current year-20.98%
1 week 1.73
Extreme 1.73
1.97
1 month 1.73
Extreme 1.73
2.19
Current year 1.56
Extreme 1.56
2.6
1 year 0.54
Extreme 0.54
7.13
3 years 0.46
Extreme 0.4603
13.51
5 years 0.46
Extreme 0.4603
14.19
10 years 0.46
Extreme 0.4603
14.19
Manager TitleAgeSince
Chief Executive Officer 59 2023-11-14
Director of Finance/CFO 50 2021-12-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 2021-12-31
Director/Board Member 67 2021-12-31
Director/Board Member 64 2021-12-31
Change 5d. change 1-year change 3-years change Capi.($)
-4.84%-7.81%+136.00%-80.57% 253M
-0.77%-2.47%-16.97%-16.79% 42.69B
+1.39%+5.91%+35.08%+32.18% 35.03B
+1.09%-1.01%+247.95%+463.28% 30.98B
+0.87%-0.77%+12.12%-6.97% 29.22B
+1.05%-2.28%+32.43%+26.70% 27.12B
-0.43%+5.49% - - 14.76B
-3.59%-3.37%+113.03%+4,035.93% 13.03B
+0.60%+0.77%+126.16%+113.55% 12.53B
+1.16%+0.78%+5.45%-1.33% 12.21B
Average -0.35%-0.32%+76.81%+507.33% 21.78B
Weighted average by Cap. +0.33%+0.38%+61.92%+341.07%

Financials

2026 *2027 *
Net sales 364K 311K 285K 270K 500K 34.88M 505K 3.39M 1.32M 16.54M 1.37M 1.34M 57.48M 359K 306K 281K 266K 493K 34.36M 497K 3.34M 1.3M 16.3M 1.35M 1.32M 56.63M
Net income -89.2M -76.08M -69.77M -66.05M -122M -8.54B -124M -831M -324M -4.05B -335M -328M -14.07B -111M -94.31M -86.5M -81.88M -152M -10.58B -153M -1.03B -401M -5.02B -415M -406M -17.44B
Net Debt -133M -113M -104M -98.46M -182M -12.73B -184M -1.24B -482M -6.04B -499M -488M -20.98B -246M -210M -192M -182M -338M -23.54B -341M -2.29B -892M -11.17B -923M -904M -38.8B
Logo ProKidney Corp.
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Employees
231
Date Price Change Volume
26-05-12 1.780 $ +0.56% 976,806
26-05-11 1.770 $ -4.84% 1,329,656
26-05-08 1.860 $ -1.06% 719,130
26-05-07 1.880 $ -4.08% 847,464
26-05-06 1.960 $ +2.08% 580,605
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.780USD
Average target price
6.250USD
Spread / Average Target
+251.12%

Quarterly revenue - Rate of surprise